Lower GI 2017

NSAPB R-04

Inclusion criteria: cT3-4 or N+ M0

Adjuvant treatment not specified

RT 50.4 Gy (@1.8Gy) + 5-FU c.i. 225 mg/m 2 /d +/- Oxaliplatin 50 mg/m 2 weekly

T M E

R

Adjuvant treatment not specified

RT 50.4 Gy (@1.8Gy) + Capecitabine 1600 mg/m 2 /d 5d/w +/- Oxaliplatin 50 mg/m 2 weekly

T M E

Primary endpoint: Time to locoregional failure Secondary: pCR, sphincter-sparing surgery, downstaging, tox